Easton Bio Pharmaceuticals 苑东生物
30 significant filings since 29 May 2026: 22 on equity incentive and 8 on buyback. The latest, on 8 Sep 2026: 苑东生物：关于回购注销2024年员工持股计划部分股份并减少注册资本暨通知债权人的公告.
自 29 May 2026 起有 30 份重大公告：equity incentive 22 份、buyback 8 份。最新一份（8 Sep 2026）：苑东生物：关于回购注销2024年员工持股计划部分股份并减少注册资本暨通知债权人的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 东吴证券 | 朱国广 | Buy 买入 | 24 Aug 2026 | 2 | — |
| 太平洋 | 谭紫媚,张懿 | Buy 买入 | 7 May 2026 | 2 | — |
| 开源证券 | 余汝意,刘艺 | Buy 买入 | 24 Apr 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 5 reports. 每行为该券商近十二个月的最新研报；5 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。